Combinational immunological checkpoint inhibitors for non-small cell lung cancer / 国际肿瘤学杂志

Immunological checkpoint inhibitors have become one of the major treatment options for patients with advanced non-small cell lung cancer (NSCLC).Despite patients with NSCLC show the superiority of standard chemotherapy in different disease settings,the response rate is still low in patients with high macromolecule selection for chemotherapy tolerance and gene mutation.This is related to the complexity and dynamics of known limited biomarkers and tumor microenvironment.Different methods of tumor cells to evade the immune system used to lay the foundation for the new combination strategy.Combination therapy not only improves the efficacy of treatment,but also makes the objective response rate improved significantly.

Progress of ALK gene inhibitors in the treatment of brain metastases from non-small cell lung cancer / 国际肿瘤学杂志

Anaplastic lymphoma kinase (ALK) rearrangement is one of the most potent carcinogenic genes in non-small cell lung cancer (NSCLC).The first-generation ALK inhibitor such as crizotinib is superior to chemotherapy for NSCLC patients with ALK rearrangement.At the same time,more and more studies have reported ALK inhibitors in brain metastases of NSCLC patients with intracranial efficiency.However,despite the initial clinical data of first-generation ALK inhibitors in the treatment of ALK-positive NSCLC with brain metastases,different degrees of recurrence of tumors after acquired resistance have posed new challenges for follow-up treatment of cancer patients.A new generation of ALK inhibitors,such as alectinib;ceritinib,AP26113 and PF-06463922 have emerged to solve this problem.